Literature DB >> 23486447

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.

J K Hicks1, J J Swen, C F Thorn, K Sangkuhl, E D Kharasch, V L Ellingrod, T C Skaar, D J Müller, A Gaedigk, J C Stingl.   

Abstract

Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23486447      PMCID： PMC3689226          DOI： 10.1038/clpt.2013.2

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  39 in total

1.  Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.

Authors:  A de Vos; J van der Weide; H M Loovers
Journal:  Pharmacogenomics J       Date:  2010-06-08       Impact factor: 3.550

2.  Association of CYP2D6 genotypes and personality traits in healthy individuals.

Authors:  Julia Kirchheiner; Undine Lang; Thomas Stamm; Thomas Sander; Jurgen Gallinat
Journal:  J Clin Psychopharmacol       Date:  2006-08       Impact factor: 3.153

3.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

4.  High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases.

Authors:  A L Zackrisson; B Lindblom; J Ahlner
Journal:  Clin Pharmacol Ther       Date:  2009-11-11       Impact factor: 6.875

Review 5.  The treatment of neuropathic pain: antidepressants and opioids.

Authors:  C P Watson
Journal:  Clin J Pain       Date:  2000-06       Impact factor: 3.442

6.  Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications.

Authors:  L Bertilsson; B Mellström; F Sjökvist; B Mårtenson; M Asberg
Journal:  Lancet       Date:  1981-03-07       Impact factor: 79.321

Review 7.  The emerging role of cytochrome P450 3A in psychopharmacology.

Authors:  T A Ketter; D A Flockhart; R M Post; K Denicoff; P J Pazzaglia; L B Marangell; M S George; A M Callahan
Journal:  J Clin Psychopharmacol       Date:  1995-12       Impact factor: 3.153

8.  The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.

Authors:  Jónrit Halling; Pál Weihe; Kim Brosen
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

9.  The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma.

Authors:  R G Cooke; J J Warsh; H C Stancer; K L Reed; E Persad
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

10.  Single-dose kinetics predict steady-state concentrations on imipramine and desipramine.

Authors:  W Z Potter; A P Zavadil; I J Kopin; F K Goodwin
Journal:  Arch Gen Psychiatry       Date:  1980-03
View more
  137 in total

1.  In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.

Authors:  Daniel L Hertz; Anna C Snavely; Howard L McLeod; Christine M Walko; Joseph G Ibrahim; Steven Anderson; Karen E Weck; Gustav Magrinat; Oludamilola Olajide; Susan Moore; Rachel Raab; Daniel R Carrizosa; Steven Corso; Garry Schwartz; Jeffrey M Peppercorn; James P Evans; David R Jones; Zeruesenay Desta; David A Flockhart; Lisa A Carey; William J Irvin
Journal:  Br J Clin Pharmacol       Date:  2015-08-02       Impact factor: 4.335

2.  CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction.

Authors:  Andrew A Monte; Kelsey West; Kyle T McDaniel; Hania K Flaten; Jessica Saben; Shelby Shelton; Farah Abdelmawla; Lane R Bushman; Kayla Williamson; Diana Abbott; Peter L Anderson
Journal:  Clin Pharmacol Ther       Date:  2018-07-25       Impact factor: 6.875

3.  Pharmacogenetics in clinical practice: how far have we come and where are we going?

Authors:  Julie A Johnson
Journal:  Pharmacogenomics       Date:  2013-05       Impact factor: 2.533

Review 4.  Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response.

Authors:  Susanne B Haga; Rachel Mills; Hayden Bosworth
Journal:  Patient Educ Couns       Date:  2014-06-21

Review 5.  Clinical association between pharmacogenomics and adverse drug reactions.

Authors:  Zhi-Wei Zhou; Xiao-Wu Chen; Kevin B Sneed; Yin-Xue Yang; Xueji Zhang; Zhi-Xu He; Kevin Chow; Tianxin Yang; Wei Duan; Shu-Feng Zhou
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

Review 6.  Eliglustat: A Review in Gaucher Disease Type 1.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

Review 7.  Pharmacogenomics in dermatology: tools for understanding gene-drug associations.

Authors:  Roxana Daneshjou; Rachel Huddart; Teri E Klein; Russ B Altman
Journal:  Semin Cutan Med Surg       Date:  2019-03-01

Review 8.  Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Authors:  Katarzyna Drozda; Daniel J Müller; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2014-02       Impact factor: 4.705

9.  Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

Authors:  Edward D Esplin; Ling Oei; Michael P Snyder
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

10.  Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.

Authors:  Celine M Laffont; Roberto Gomeni; Bo Zheng; Christian Heidbreder; Paul J Fudala; Azmi F Nasser
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.